BioLight Life Sciences Ltd. ADR (BLGTY)

[midastouch017]

BioLight’s Eye-D Technology to be Featured at the 5th Annual Partnership Opportunities in Drug Delivery Conference in Boston
PR Newswire BioLight Life Sciences Investments

TEL-AVIV, Israel, September 24, 2015 /PRNewswire/ --

BioLight Life Sciences Investments (OTCQX: BLGTY, TASE: BOLT) ("BioLight" or the "Company"), a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced today that its Eye-D platform insert will be presented at the 5th Annual Partnership Opportunities in Drug Delivery ("PODD") conference on Monday, October 5, 2015 at 2:00 p.m. Eastern Time at the Boston Intercontinental Hotel in Boston, MA.

The Eye-D is BioLight's platform insert for controlled release ophthalmic medications. The Eye-D is designed to address the known poor compliance of eye drops administration. The first Eye-D indication, the VS-101, contains the market leading glaucoma drug, latanoprost (Pfizer Inc.'s Xalatan®). Utilizing a simple in-office procedure, the VS-101 is intended to release prostaglandin analog (PGA) drug in a controlled manner over time, providing 100% patient compliance to drug therapy.

PODD 2015 seeks to foster a meeting place that inspires innovation and advancement of drug development and delivery as well as providing support for the leaders behind the movement. For more information on the conference, please visit http://theconferenceforum.org/conferences/partners-in-drug-delivery/agenda/.